A5005398528- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Estrogen and related hormone effects
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Cancer Cells and Metastasis
- Chronic Lymphocytic Leukemia Research
- Breast Lesions and Carcinomas
- Metabolism, Diabetes, and Cancer
- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Cancer therapeutics and mechanisms
- Growth Hormone and Insulin-like Growth Factors
- Cancer-related Molecular Pathways
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
Ospedale Infermi di Rimini
2014-2024
Fondazione Michelangelo
2017-2021
IRCCS Ospedale San Raffaele
2007-2018
Ospedale degli Infermi
2005-2018
Azienda Ospedaliera Universitaria Integrata Verona
2018
Ospedale di Bolzano
2018
Ospedale Sacro Cuore Don Calabria
2018
Istituti Ospitalieri di Cremona
2018
Azienda Ospedaliera S.Maria
2018
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2018
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
Predicting the pattern of recurrence can aid in development targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event a median follow-up 24 years from diagnosis operable breast cancer.International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 1985. Annualized hazards were estimated cancer-free interval (primary end point), disease-free survival, overall survival.For entire group,...
Abstract DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 history treated brain metastases (BM), population limited treatment options. In BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%–77.9%], and median progression-free survival (mPFS) 18.1 months (95% CI, 6.7–18.1 months). without BMs (n = 160), cORR...
Summary The prognostic value of 12 clinical and haematological parameters, recorded at diagnosis, in myelofibrosis with myeloid metaplasia (MMM) was retrospectively analysed a consecutive series 133 patients followed for minimum 60 months. Multivariate analysis showed that the following features were associated significantly shorter survival: (1) short period time (<13 months) between first symptoms diagnosis; (2) anaemia (haemoglobin <10 g/dl); (3) leucocyte count >12 × 10 9 /l;...
Purpose To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity few adverse effects in advanced breast cancer, early cancer. Patients Methods International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor– progesterone receptor–negative (< 10% positive cells by...
In spite of the effectiveness endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitors as first-line treatment for estrogen receptor (ER)-positive, erb-b2 tyrosine 2 (ERBB2 [formerly HER2/neu])-negative (ER+/ERBB2-) metastatic breast cancer (MBC), patients eventually develop resistance, and most will receive chemotherapy. The METEORA-II trial compared a metronomic all-oral with intravenous (IV)
1026 Background: P is a humanized monoclonal antibody that binds to the specific dimerization epitope of HER2, blocking HER2 homo- and heterodimerization, thus preventing signal transduction. Xenograft studies indicate complementary mechanisms action H have synergistic effect. Methods: This single-arm, Simon-type, two-stage phase II trial included pts with measurable, centrally tested HER2-positive MBC, ≥3 lines prior therapy (including adjuvant therapy), disease progression during therapy,...
There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of "standard chemotherapy regimens" such as AC or CMF. The CASA trial studied pegylated liposomal doxorubicin (PLD) low dose, metronomic cyclophosphamide + methotrexate (CM) older (>65), vulnerable operable, ER PgR-negative cancer. After two years the closed early, due to slow inadequate accrual, 77 patients (38:PLD, 36:CM, 3:nil)....
The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with either trastuzumab or lapatinib. Here, we report post hoc survival analysis as per treatment arm, pCR and biomarkers.The 121 patients human epidermal growth factor receptor 2-positive, stage II-IIIA breast cancer. A specific protocol to collect recurrence-free (RFS) overall (OS) data was designed. Tumour-infiltrating...
513 Background: In the mid 1990's data indicated that paclitaxel had marked antitumor activity in metastatic breast cancer, justifying attempt at investigating whether taxane could improve therapeutic benefit of established regimens early cancer Methods: From 1996 to 2002 a total 1355 women with operable (T>2cm) were randomized adjuvant A (75 mg/m2 q21d x 4) followed by i.v. CMF (day 1&8 q28d 4), or (60 mg/m2) and T (200 over 3 hrs (AT→CMF), AT→CMF as primary systemic therapy (PST). Results:...
Abstract BACKGROUND Others have reported ocular toxicity after adjuvant chemoendocrine therapy, but this study looked at in similarly treated patients from large randomized clinical trials. METHODS Information was retrieved on incidence and timing of the International Breast Cancer Study Group (IBCSG) database 4948 eligible to receive tamoxifen or toremifene alone combination with chemotherapy (either concurrently sequentially). Case reports were evaluated determine whether occurred during...
Summary To evaluate the occurrence of hypercoagulability during treatment with l ‐asparaginase ( ‐ase), thrombin‐antithrombin complex (TAT) and d ‐dimer levels in plasma were serially measured 15 consecutive adult patients acute lymphoblastic leukaemia or lymphoma who had recently completed a chemotherapy cycle cytosine arabinoside methotrexate. The first eight (group A) received i.v. ‐ase alone (20000 U/m 2 on alternate days over 10 d); last seven B) received, addition to ‐ase, bolus...
The introduction of cisplatin in cancer treatment represents an important achievement the oncologic field. Many types cancers are now treated with this drug, and testicular patients major results reached. Since 1965, other compounds were disovered among them carboplatin oxaliplatin main Cisplatin analogues showing similar clinical efficacy a safer toxicity profile. Lipoplatin is new liposomal formulation which seems to have these characteristics. was shown be effective NSCLC both phase 2 3...
The aim of this study was to improve activity over single human epidermal growth factor receptor 2 (HER2)-blockade sequential neaodjuvant regimens for HER2-positive breast cancer, by exploiting the concomitant administration trastuzumab, taxane and anthracycline, while restraining cardiac toxicity with use liposomal doxorubicin, adding metformin, based on preliminary evidence antitumor activity.This multi-center, single-arm, two-stage phase II trial, assessed safety a new treatment regimen...
Hemostatic abnormalities are rather frequent in cancer patients either hematological or solid tumors. Acute disseminated intravascular coagulation (DIC) is a rare coagulopathy patients, but when it develops becomes rapidly fatal. Between June 1988 and December 1992 we observed 8 cases of acute DIC occurring gastric (4 patients), breast (3 patients) high-grade non-Hodgkin lymphoma (1 patient). In 3 affected by carcinoma, was the first manifestation presence tumor, while other occurred during...